Lv61
2770 积分 2021-09-15 加入
Sacituzumab govitecan (IMMU‐132), an anti‐Trop‐2‐SN‐38 antibody‐drug conjugate for the treatment of diverse epithelial cancers: Safety and pharmacokinetics
11天前
已完结
An anti–TNF–glucocorticoid receptor modulator antibody-drug conjugate is efficacious against immune-mediated inflammatory diseases
11天前
已完结
Re-Evaluating Antibody–Drug Conjugate Linker Stability: Assessment, Interpretation, and Clinical Translation
1个月前
已完结
Re-Evaluating Antibody–Drug Conjugate Linker Stability: Assessment, Interpretation, and Clinical Translation
1个月前
已关闭
The Osmolality and Hemolysis of High-Concentration Monoclonal Antibody Formulations
1个月前
已完结
Non-ideal osmolality behavior in high-concentration protein formulations: mechanistic insights from freezing-point depression, vapor-pressure deficit, and molecular dynamics simulations
1个月前
已关闭
Considerations for Antibody-Drug Conjugate Design: Stability and Formulation
3个月前
已完结
Formulation Development for Antibody–Drug Conjugates
3个月前
已完结
Formulation and Stability
4个月前
已完结
1496 JSKN033, an innovative subcutaneous-injected fixed-dose combination (FDC) of biparatopic anti-HER2 antibody drug conjugate (ADC) and PD-L1 inhibitor in advanced solid tumor
4个月前
已完结
皖公网安备34019202002308
